Form 4: Precigen Chief Commercial Officer Granted 250,000 Stock Options

Precigen, Inc.'s Chief Commercial Officer, Phil Tennant, was granted 250,000 stock options with an exercise price of $1.37, vesting over a four-year period.

Summary

• Phil Tennant, Chief Commercial Officer of Precigen, Inc. (PGEN), was granted 250,000 options to purchase common stock.
• The transaction date for this grant was May 23, 2025.
• The exercise price for these options is $1.37 per share.
• The options will vest 50% on May 23, 2026, with the remaining portion vesting in equal monthly installments over the subsequent three years.
• The options have an expiration date of May 23, 2035.
• Following this transaction, Phil Tennant beneficially owns 250,000 derivative securities (options).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the interests of a key executive with shareholders, which is generally viewed favorably. It does not, however, provide direct financial performance data.

Positives

• The grant of stock options to the Chief Commercial Officer aligns management's long-term interests with those of shareholders, incentivizing performance and growth.
• The options were granted at a price of $0, indicating they are part of a compensation package rather than a purchase, which is a common practice for executive incentives.

Future Outlook

The grant of long-term stock options suggests an expectation of future value creation and continued employment for the Chief Commercial Officer, aligning his incentives with the company's long-term performance.

Industry Context

This Form 4 filing is a standard disclosure of an insider equity transaction, common in publicly traded companies, particularly in the biotechnology sector like Precigen, where executive compensation often includes stock-based incentives to align with long-term R&D and commercialization goals.

Related Party Transactions

• The grant of 250,000 stock options to Phil Tennant, the Chief Commercial Officer, constitutes a related party transaction as it involves the company and a key executive.

Stakeholder Impact

• Shareholders: The grant of options could lead to future dilution if exercised, but also aligns management incentives with shareholder value creation.
• Employees (specifically the Chief Commercial Officer): This grant represents a significant component of his long-term compensation and incentive structure.

Next Steps

• The options will begin vesting on May 23, 2026, with subsequent monthly vesting installments over three years.

Key Dates

Keywords

Precigen, PGEN, Stock Options, Insider Transaction, SEC Form 4, Phil Tennant, Chief Commercial Officer, Equity Compensation, Beneficial Ownership